Michael Okunewitch
Stock Analyst at Maxim Group
(0)
# 4717
Out of 5,253 analysts
22
Total ratings
22.22%
Success rate
-19.33%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Lineage Cell Therape... | Maintains: Buy | 5 3 | 0.61 | 391.8% | 1 | Jan 10, 2025 | |
Citius Oncology | Initiates Coverage On: Buy | 3 | 1.2 | 150% | 1 | Nov 27, 2024 | |
Ocugen | Initiates Coverage On: Buy | 4 | 0.71 | 463.38% | 1 | Oct 15, 2024 | |
FibroBiologics | Initiates Coverage On: Buy | 12 | 1.59 | 654.72% | 1 | Sep 24, 2024 | |
Longeveron | Maintains: Buy | 15 6 | 1.59 | 277.36% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 4 | 2.09 | 91.39% | 1 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 3 12 | 1.7 | 605.88% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 2 | n/a | n/a | 1 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 24 | 5.3 | 352.83% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 6 | 1.5 | 300% | 1 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 108 18 | 3.62 | 397.24% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 225 | 1.11 | 20170.27% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 25 | 20.45 | 22.25% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 6 | 2.25 | 166.67% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 4 | 0.31 | 1190.32% | 1 | Mar 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 120 | n/a | n/a | 1 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 25 | 1.4 | 1685.71% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 100 | 2.81 | 3458.72% | 1 | Nov 30, 2021 |